These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30473665)

  • 1. Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells.
    Tzeng YT; Liu PF; Li JY; Liu LF; Kuo SY; Hsieh CW; Lee CH; Wu CH; Hsiao M; Chang HT; Shu CW
    Front Pharmacol; 2018; 9():1285. PubMed ID: 30473665
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells.
    Chang CC; Chiu CC; Liu PF; Wu CH; Tseng YC; Lee CH; Shu CW
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
    Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L
    PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methoxyhispolon Methyl Ether, a Hispolon Analog, Thwarts the SRC/STAT3/BCL-2 Axis to Provoke Human Triple-Negative Breast Cancer Cell Apoptosis In Vitro.
    Liao CP; Hsieh YC; Lu CH; Dai WC; Yang WT; Cheng KT; Ramani MV; Subbaraju GV; Chang CC
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation.
    Sato F; Sagara A; Tajima K; Miura S; Inaba K; Ando Y; Oku T; Murakami T; Kato Y; Yumoto T
    Breast Cancer Res Treat; 2022 Jul; 194(2):243-256. PubMed ID: 35624176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.
    Tan Q; Wang H; Hu Y; Hu M; Li X; Aodengqimuge ; Ma Y; Wei C; Song L
    Cancer Sci; 2015 Aug; 106(8):1023-32. PubMed ID: 26041409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
    Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
    Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
    Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
    Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
    Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer.
    Wang L; Yang C; Liu XB; Wang L; Kang FB
    Cancer Cell Int; 2018; 18():100. PubMed ID: 30008617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells.
    Huang P; Ouyang DJ; Chang S; Li MY; Li L; Li QY; Zeng R; Zou QY; Su J; Zhao P; Pei L; Yi WJ
    Cell Commun Signal; 2018 Nov; 16(1):92. PubMed ID: 30497491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
    Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
    Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
    Cancer Metab; 2017; 5():6. PubMed ID: 28852500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells.
    Sapio L; Sorvillo L; Illiano M; Chiosi E; Spina A; Naviglio S
    Molecules; 2015 Sep; 20(9):15910-28. PubMed ID: 26340617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.